Physician

Peter Gable Manring, MD

According to 2025 Medicare claims, Peter Manring, MD (NPI: 1396864401) practices nephrology in the Kalamazoo-Portage, MI market, with the plurality of this provider's patient population coming from Kalamazoo, MI. This provider's primary affiliated billing organization is PARAGON HEALTH, PC (NPI: 1083678767; TIN: 383309299) and primary practice location at 49010-8507. Manring is affiliated with the West Michigan Accountable Care Organization, LLC (ACO ID: A4626), participating under the MSSP model.

Manring's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 315 traditional Medicare patients, billed 1,001 HCPCS/CPT codes, and received $127,984 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 3,947 prescription claims across 489 beneficiaries totaling $606,399 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 49 claims. Open Payments data shows 2 records totaling $47. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $213,680 to $127,984. In contrast, Part D prescription costs have risen steadily, from $256,288 to $606,399. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	689	2,156	$213,680
2016	693	2,078	$198,855
2017	667	1,987	$178,448
2018	606	1,694	$160,456
2019	606	1,547	$151,450
2020	519	1,303	$132,927
2021	473	1,289	$149,499
2022	400	1,277	$163,031
2023	349	1,098	$147,751
2024	315	1,001	$127,984

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	422	3,168	$256,288
2016	453	3,667	$303,718
2017	462	3,605	$341,142
2018	477	3,761	$305,870
2019	474	3,663	$227,873
2020	474	3,560	$269,716
2021	502	4,010	$306,050
2022	505	4,156	$440,540
2023	499	4,020	$472,313
2024	489	3,947	$606,399

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	109	$6,788
2016	N/R	99	$4,488
2017	N/R	125	$6,366
2018	N/R	157	$8,419
2019	N/R	178	$13,016
2020	N/R	197	$6,935
2021	N/R	110	$3,816
2022	N/R	111	$3,050
2023	N/R	91	$2,001
2024	N/R	49	$1,046

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	37	244	$261
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	40	40	$121
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	32	33	$97
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	52	101	$58
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	168	265	$52

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	98	5,227	$92,858
Jardiance	Empagliflozin	81	4,826	$92,046
Xphozah	Tenapanor Hcl	21	870	$84,364
Kerendia	Finerenone	73	3,554	$74,869
Velphoro	Sucroferric Oxyhydroxide	27	870	$61,079

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	16	$532
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	17	$301
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	16	$213

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$47	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Peter Gable Manring, MD?

Tedicare shows public-source Medicare data for Peter Gable Manring, MD (NPI 1396864401), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Peter Gable Manring, MD have ACO affiliation data?

Peter Gable Manring, MD is shown with ACO affiliation data for West Michigan Accountable Care Organization, LLC (MSSP, ACO ID A4626).

What billing organization is linked to Peter Gable Manring, MD?

Peter Gable Manring, MD is linked to PARAGON HEALTH, PC (billing NPI 1083678767) in the available physician profile data.

Does Peter Gable Manring, MD have Open Payments data?

Peter Gable Manring, MD has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.